Clinical Scorecard: Stellest® Named One of TIME’s Best Inventions of 2026

At a Glance

Key Highlights

• TIME named Essilor’s Stellest® lenses one of its Best Inventions of 2026 in the Health & Wellness category.
• The FDA granted Stellest® De Novo market authorization in September 2025.
• The article describes Stellest® as the first and only FDA market-authorized spectacle lenses in the United States to slow myopia progression in children.
• Stellest® received FDA Breakthrough Device designation in 2021.
• The article states that progressive myopia can affect long-term eye health.

Guideline-Based Recommendations

Diagnosis

• The article emphasizes regular eye exams and professional guidance but does not provide diagnostic criteria.

Management

• The article reports that Stellest® lenses received FDA market authorization to slow myopia progression in children.

Monitoring & Follow-up

• The article describes regular eye exams as essential.

Risks

• The article states that progressive myopia can affect long-term eye health.

Patient & Prescribing Data

Children with myopia; the article provides no further eligibility or prescribing details.

Stellest® is described as spectacle lenses authorized by the FDA in September 2025 to slow myopia progression in children. The article provides no dosing, fitting, or follow-up protocol.

Clinical Best Practices

• The article emphasizes regular eye exams for children.
• The article emphasizes professional guidance regarding childhood myopia.

Related Resources & Content